<a href="https://laohu8.com/S/ANRO">Alto Neuroscience</a> Announces Phase 2b Trial Launch of ALTO-207 for Treatment-Resistant Depression, Backed by New Lancet Psychiatry Study
Alto Neuroscience Inc. has announced the upcoming initiation of a Phase 2b clinical trial for their drug ALTO-207, expected to start by mid-2026. ALTO-207 is a fixed-dose combination of pramipexole and ondansetron, designed to achieve rapid antidepressant effects in patients with treatment-resistant depression $(TRD.UK)$ while mitigating adverse events associated with pramipexole alone. This trial follows the publication of results from the PAX-D study in The Lancet Psychiatry, which demonstrated significant symptom reduction in TRD patients using pramipexole, though accompanied by a high rate of adverse effects. Alto plans to collaborate with the National Health Service and PAX-D clinical sites for the trial. The study results have already been presented during an investor conference call by Alto Neuroscience.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250630531248) on June 30, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。